Clinical

News on 2 new CAR T-cell therapies and updates on PARP inhibitors, BTK inhibitors, and biosimilars.

Results of the phase 3 ALPINE trial provided found zanubrutinib was superior to ibrutinib in overall response rate.

While studies have explored risks among patients with multiple myeloma, recent research is the first to compare cardiovascular mortality risk in multiple myeloma to that of the general population.

Experts in behavioral health discuss overcoming barriers to access for alternative therapies for TRD including the Risk Evaluation and Mitigation Strategy (REMS) requirement for intranasal esketamine.

Dr Patricia Ares-Romero and Dr Martin Rosenzweig discuss treatment strategies for TRD, including alternative therapies and explain current barriers within the healthcare system that inhibit access.

Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, explains current knowledge on the pathology of atopic dermatitis and use of targeted biologic therapies.

The research could pave the way for therapies that target enhancers of disease-related genes.

Editor’s Note: After this issue of Evidence-Based Oncology™ went to press, Bristol Myers Squibb Foundation announced the $100 million, 5-year initiative will now be called the Robert A. Winn Diversity in Clinical Trials Award Program. The program will also receive a $14 million donation from Gilead Sciences, Inc., over the next 4 years.

Researchers presented results for ZB131, a monoclonal antibody that would target cancer-specific plectin (CSP); experiments with mice showed this may be present in more than 80% of the most common types of cholangiocarcinoma.

The researchers found that the prognostic values for both overall and progression-free survival remained even after adjusting for the International Prognostic Index, a widely used prognostic model of outcomes for the disease.

Camille Hertzka, vice president, head of oncology, US Medical, AstraZeneca, clarifies testing for the HRR mutation in metastatic castrate-resistant prostate cancer (mCRPC) and the predictive importance of radiographic progression-free survival (rPFS) for overall survival in this setting.

Based on the analysis of electronic health records from 480 clinics, we found that better care quality and continuity are associated with better-than-expected wound healing performance.

In patients with intermediate- to high-risk, use of pegfilgrastim biosimilars could optimize management of FN risk.

Dr Beveridge explains potential barriers a physician can encounter when implementing RWE into MM therapy.

The panel elaborate on how they’ve incorporated RWE into their decision-making processes for their patients with MM.

Across 3 disease states, dupilumab has been shown to create rapid, clinically meaningful responses that were sustained, which could improve adherence and the patient-provider relationship.

In this study, the authors developed a method for use in primary care to identify a group of patients with complex care needs using Aggregated Diagnosis Groups.

Kristin Highland, MD, discusses the common risk factors associated with ILD.

Paul Noble, MD, and Daniel Culver, DO, explain the definition of interstitial lung disease (ILD), as well as certain conditions that fall within that distinction.

The authors studied the impact of a pharmacist intervention on blood pressure control compared with usual care.

While teprotumumab, a new FDA-approved therapy for thyroid eye disease (TED), has its adverse events, the other options to treat TED can have severe consequences, said Shoaib Ugradar, MD, UCLA Stein Eye Center Santa Monica.

With further research, allogeneic CAR T-cell therapy may help overcome the cost and production time barriers currently associated with autologous CAR T-cell therapy.

Circulating B cell–activating factor was shown to be a potential biomarker in identifying blood eosinophil counts and risk of postoperative nasal polyp recurrence among patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

Therapy resistance remains a challenge with immune checkpoint inhibitors, and a new study proposes targeting ligand-dependent corepressor (LCOR) in addition to known immune targets to improve outcomes.

Genetically predicted insomnia is a risk factor for allergic disease and asthma, according to a recent Mendelian randomization study.